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Abstract
Chronic  lymphocytic  leukemia  (CLL)  is  hematopoietic  malignancy  involving  clonal  proliferation  and
accumulation of morphologically mature yet functionally incompetent B-lymphocytes in blood, lymphoid tissue
and, less commonly, extralymphatic organs. Despite significant advances in molecular characterization of CLL,
the pathogenesis of the disease remains incompletely understood.  Besides disturbed apoptosis considered to be
the main molecular defect responsible for the development of CLL, some role is also attributed to activation of
BCR receptor,  triggering of PI3K and MEK/ERK signaling pathways, and activation of nuclear transcription
factor κB (NF-κB) which result in increased proliferation of leukemic cells. Intracellular activation pathwaysB (NF-κB (NF-κB) which result in increased proliferation of leukemic cells. Intracellular activation pathwaysB) which result in increased proliferation of leukemic cells. Intracellular activation pathways
may also be triggered by other proteins, including proteins of the TNF family. B cell activating factor (BAFF)
and its  homolog A proliferation inducing ligand (APRIL) are cytokines  of the tumor necrosis  factor  (TNF)
family considered to play the key role in regulation of biological function of B-lymphocytes. Interactions of both
molecules with their receptors (BAFF-R, TACI, BCMA) promote survival of normal B-lymphocytes while also
affecting their differentiation, maturation, chemotaxis, class switching and antibody production. According to
current knowledge, malignant B-lymphocytes responsible for CLL are characterized by upregulation of these
proteins and receptors which translates into deregulation of apoptosis and proliferation of cells, higher stage of
the  disease,  and  poorer  prognosis.  This  article  summarizes  current  knowledge  on  the  characteristics  and
physiological importance of BAFF, APRIL and their receptors as well as on the established role of these proteins
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in the pathogenesis of chronic lymphocytic leukemia including deregulation of leukemic B-lymphocytes together
with the potential for BAFF and APRIL proteins being used as prognostic markers in clinical medicine.
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1. Introduction
Chronic  lymphocytic  leukemia  (CLL)  is  hematopoietic  malignancy  involving  clonal  proliferation  and
accumulation of morphologically mature yet functionally incompetent B-lymphocytes in blood, lymphoid tissue
and, less commonly, extralymphatic organs [1]. CLL is the most common type of leukemia in the overall adult
population of the Western countries, with its morbidity rates continuously increasing [2]. The median age at CLL
onset is in the range of 67-72 years, with more than 70% of patients being over the age of 70 at the time of
diagnosis [1,3]. Despite the disease being chronic by definition, it is characterized by significant heterogeneity of
natural  history.  While  some  patients  present  with  slow  disease  development  and  long  times  to  disease
progression, others require treatment immediately or shortly after being diagnosed, their disease following a very
aggressive course [4,5]. Leukemic cells have the phenotype of small, mature B-lymphocytes characterized by
expression of CD19, CD20, CD23, or CD5 surface markers. The majority of these cells are arrested at the G0
stage of the cell cycle [2]. At the same time, part of cells within the bone marrow and peripheral  lymphatic
organs present with potential for proliferation contributing to the pool of leukemic B-lymphocytes in the course
of the disease. Disturbed apoptosis was generally considered to be the main molecular defect responsible for the
accumulation of B-lymphocytes and the development of CLL, with survival of lymphatic cells being attributed
to disruption of apoptotic pathways as well as increased responsiveness to pro-survival factors [6]. In recent
years, an additional factor which determines the dynamics of the disease was identified, consisting in the cells’
active  proliferation  ability  triggered  by  activation  of  the  BCR  receptor  by  a  hitherto  unknown  endo-  or
exogenous factors [1]. Despite significant advances in characterization of molecular defects responsible for CLL,
the pathogenesis of the disease remains incompletely understood.  In recent years, proteins of the tumor necrosis
factor (TNF) family became the object of research interest in the context of their physiological role as well as
their involvement in deregulation of B-lymphocytes in the course of CLL, other lymphoproliferative diseases,
and humoral immunity deficiencies. B cell activating factor (BAFF) and its homolog a proliferation inducing
ligand (APRIL) are cytokines of the tumor necrosis factor (TNF) family which, by interacting with their specific
receptors, regulate the biological function of B-lymphocytes in physiological conditions [7]. As shown in studies
published to date, the expression of these proteins on the surface of CLL B-cells is significantly higher than on
the physiological B-cells in healthy subjects, contributing to the increased survival and proliferation potential of
the leukemic  cells.  This  article  summarizes  current  reports  on the  involvement  of  BAFF,  APRIL and their
receptors in the mechanisms responsible for of leukemic B-lymphocytes and their impact on the development of
chronic lymphocytic leukemia.
2. Objective, materials, and methods
The aim of this study was to summarize current knowledge on BAFF, APRIL, and their receptors with
respect  to  their  physiological  role  as  well  as  their  involvement  in  the  pathogenesis  of  chronic lymphocytic
leukemia.  Included  in  the  review are  the  reports  on protein  structure  characterization,  molecular  effects  of
ligand-receptor  interactions,  the  role  of  these  interactions  in  deregulation  of  leukemic  B-lymphocytes,  and
potential future clinical applications of the collected knowledge. Literature search was carried out by means of a
PubMed database query.
3. Discussion
3.1. Pathogenesis of chronic lymphocytic leukemia (CLL)
As  mentioned  before,  chronic  lymphocytic  leukemia  (CLL)  is  a  malignancy  of  the  lymphoid  system
associated with clonal proliferation of morphologically mature yet functionally incompetent B-lymphocytes; in
the course of the disease, these cells are found within blood, bone marrow, peripheral lymphatic organs and
lymphoid tissue (lymph nodes and nodules) and, less commonly, extralymphatic organ infiltrates. According to
2008  WHO  classification,  CLL  is  a  malignancy  of  the  lymphatic  system  originating  from  peripheral  B-
lymphocytes  [1].  In  general,  leukemic  B-lymphocytes  phenotypically  correspond  to  mature  peripheral  B-
lymphocytes  as  evidenced  by the set  of  surface  antigens  including CD19,  CD20,  and  CD23;  they are  also
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characterized  by  low  expression  of  surface  immunoglobulins  [2].  At  the  same  time,  leukemic  cells  are
characterized by expression of CD5; this antigen is present only in a small subpopulation of physiological B-
lymphocytes (B1 cells). Over the last several years, the origin of the leukemic cells in the course of CLL has
been widely discussed. Gene expression profiling suggests high similarity between CLL B-cells and CD5+ cells
of healthy adults; it appears that leukemic B-cells with no mutations within the immunoglobulin heavy chain
variable region gene (IgVH) originate from CD5+CD27− (classical memory cells) with the same IgVH mutation
status whereas B-cells with mutations within the IgVH gene originate from the less studied subpopulation of
CD5+CD27+ cells featuring IgVH mutations. It is estimated that a vast majority (ca. 95-97%) of leukemic cells
are arrested at  the G0/G1 stage of the cell cycle which is responsible for the relative resistance of CLL to
standard cytostatic drugs as observed in numerous cases [6]. According to the traditional explanation, the main
factor responsible for CLL pathogenesis was considered to consist in disturbed apoptotic pathways. Leukemic B-
lymphocytes present with overexpression of B-cell lymphoma 2 (Bcl-2) protein and aryl hydrocarbon receptor-
interacting  protein  (AIP)  along  with  reduced  levels  of  proapoptotic  Bcl-2-associated  X  (BAX)  and  Bcl-2
antagonist/killer (BAK) proteins, resulting in reduced permeability of mitochondrial membranes and reduced
secretion of cytochrome c, ultimately inhibiting mitochondrial  apoptosis [8]. In recent years, involvement of
excessive proliferation of B-lymphocytes within the lymph nodes and bone marrow has also been highlighted;
the process is dependent on the B-cell receptors (BCRs) and the microenvironment of lymphatic organs [9].
Stimulation of BCR activates Lck/Yes novel tyrosine kinase (LYN) and spleen tyrosine kinase (SYK) which
phosphorylate  immune-receptor  tyrosine-based  activatory  motifs  (ITAMs)  within  BCR-bound  CD79a  and
CD79b proteins.  Phosphorylated ITAMs recruit  adaptor proteins such as  Bruton tyrosine kinase (BTK) and
phosphoinositol 3-kinase (PI3K) which in turn activate mammalian target  of rapamycin (mTOR) kinase and
protein kinase B (PKB, Akt) and ultimately nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB (NF-κB) which result in increased proliferation of leukemic cells. Intracellular activation pathwaysB)  which triggers the transcription of genes responsible for cell activation and proliferation [10]. In about one
half of patients, leukemic cells also express ZAP-70 (ζ-associated protein of 70 kDa) kinase which additionally
promotes the recruitment of adaptor kinases to BCRs and facilitates transduction of signals to the interior of cells
[11]. As the result of BCR activation, leukemic cell is provided not only with increased ability to proliferate, but
also with increased expression of chemokines such as CCL3 and CCL4 which recruit other cells facilitating the
survival of leukemic cells, such as regulatory T cells, into the microenvironment [12]. Besides lymphocytes T,
proliferating  leukemic  cells  remain  in  close  contact  with  numerous  cells  within  their  immediate
microenvironment  in  the  lymphatic  organs,  including  mesenchymal  stem  cells  and  monocyte/macrophage-
derived cells (nurse-like cells) [10]. Interestingly, leukemic cells present with increased activation of not only
BCRs,  but  also  of  TNF  family  receptors  (TNF-R)  such  as  B  cell-activating  factor  receptor  (BAFF-R),
transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and B cell maturation
antigen (BCMA), with the aforementioned BAFF and APRIL proteins acting as ligands thereof [13].
3.2. Characterization of selected TNF superfamily proteins and their receptors
TNF superfamily is a complex group of cytokines which currently consists of 19 proteins with structural and
functional analogies. These cytokines exert complex impact on survival, differentiation, and numerous functions
of immune cells in the course of inflammatory processes or specific immune responses [14]. The members of the
superfamily include molecules involved in positive regulation of cell apoptosis (FASL, TRAIL) or lysis (LTα,
LTβ), pyrogens (TNFα), and stimulators of differentiation and proliferation of T-lymphocytes (CD27L, CD30L,), pyrogens (TNFα), and stimulators of differentiation and proliferation of T-lymphocytes (CD27L, CD30L,
4-1BBL, OX40L) as well as B-lymphocytes (CD40L). The proteins of interest in this review, BAFF and APRIL,
are TNF superfamily members which have been discovered only several years ago and which play a crucial role
in regulation of B cell homeostasis. 
B cell activator factor (BAFF), also known as B lymphocyte stimulator (BlyS), TNF and apoptosis ligand-
related leukocyte-expressed ligand 1 (TALL-1), or CD257 is a 285-amino acid molecule which may be found in
cell membrane-bound or soluble secreted form [7]. The membrane-bound form of BAFF consists of cytoplasmic,
transmembrane, and extracellular domains; the latter domain contains sequences shared by all TNF superfamily
members [15]. An unique feature of BAFF consists in its ability to assemble in trimeric but also up to 60-meric
forms referred to as viral-like forms and characterized by higher receptor binding strengths [7,15]. Although
BAFF is produced mainly in B cells follicular T helper (fTh) cells and myeloid-line cells, it is expressed in most
cells of all types of tissues [6]. Thanks to its continuous expression BAFF facilitates constant positive regulation
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of B cell survival and function; the expression is increased by the presence of inflammatory cytokines (IFNα,
IFNγ, G-CSF, IL-10), stimulation of Toll-like receptor 3 (TLR3) or interactions between T and B cells mediated
by CD40-CD40L molecules in the process of physiological B cell activation [16,17]. 
A member proliferation-inducing ligand (APRIL), also known as TALL-2 or CD256, is a 250-amino acid
homolog  of  BAFF  sharing  about  30%  of  TNF  superfamily-homologous  sequences  present  within  the
extracellular domain of BAFF [7]. Notably, in the contrary to BAFF, APRIL contains the short alkaline amino
acid  sequence  which  facilitates  binding  of  proteoglycans  present  within the  cell  microenvironment  [7,  18].
APRIL is found mainly in the form of homotrimers; however, a heterotrimeric form (consisting of APRIL and
BAFF molecules) is also known and encountered mainly in autoimmune diseases [19]. In contrast to BAFF,
APRIL is rarely expressed on the cell membrane, being usually present either in soluble form or bound to the
Golgi  apparatus  [20,  21].  APRIL  is  produced  mainly  by  myeloid-line  cells,  B  cells,  epithelial  cells,  and
osteoclasts. Particularly high expression of APRIL has been observed for dendritic cells exposed to interferons
(IFN-α, IFN-γ) or interaction with CD40L [22]. 
The biological effects of BAFF and APRIL are triggered by their interactions with appropriate receptors.
The best-studied receptors for the BAFF and APRIL ligands include the aforementioned BAFF-R, TACI, and
BCMA. B cell-activating factor receptor (BAFF-R), also referred to as BAFF receptor 3 (BR3) or CD268, is a
small membrane molecule of the TNF-R family found on the surface of B-lymphocytes as well as activated T-
lymphocytes and regulatory T-lymphocytes [23,24]. Out of the entire population of human B cells, the highest
expression of BAFF-R is observed on naive B cells and memory B cells; the receptor is absent only from the
surface of plasma cells [24]. The structure of the receptor corresponds to that of most TNF-Rs with a certain
difference  consisting  in  a  lower  number  of  cysteine-rich  domains  (CDRs)  within  the  extracellular  domain,
making BAFFF the preferred ligand for stable binding [25]. Interactions with ligands activates TNF-receptor
associated factor 3 (TRAF-3) which in turn activates NF-κB (NF-κB) which result in increased proliferation of leukemic cells. Intracellular activation pathwaysB along with its pro-cell survival, pro-proliferative,
pro-cell activation and pro-differentiation effects [22, 24, 26].
Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) is a membrane
protein present mainly on the surface of memory B cells and macrophages [27, 28]. The effects exerted by TACI
largely depend on the connected ligand. Binding of a BAFF molecule is known to downregulate the function of
mature lymphocytes, reducing their ability to survive, proliferate, and produce antibodies [27]. On the other hand
binding of an APRIL molecule results in a series of counteracting effects starting from increased cell survival,
ability  to  antibody  class  switching  and  somatic  hypermutations  within  the  first  days  of  antigen-dependent
lymphocyte activation [29-31]. TACI binding affects activation of TRAF-2, TRAF-5, TRAF-6, c-jun N-terminal
kinase (JNK) and, consequently, activation of NF- κB (NF-κB) which result in increased proliferation of leukemic cells. Intracellular activation pathwaysB as well as nuclear factor of activated T-cells (NF-AT) and
activator protein 1 (AP-1), featuring a survival regulating-function [29].
B-cell maturation antigen (BCMA) is a membrane receptor protein with a structure analogous to that of
other  TNF-R family  receptors.  The  reports  on  the  exact  structure  and  function  of  BCMA are  sparse.  The
molecule is known to undergo expression mainly on the surface of mature B lymphocytes. In a manner similar to
BAFF-R and TACI, it is involved in regulation of survival and proliferation of these cells [32]. Biological effects
are mediated by activation of TRAF-1, TRAF-2, and TRAF-3, activation of mitogen-activated protein kinase 8
(MAPK-8) and JNK, and activation of transcription factors NF-κB (NF-κB) which result in increased proliferation of leukemic cells. Intracellular activation pathwaysB and Ets-like transcription factor 1 (Elk-1)
[32]. 
3.3. The role of BAFF, APRIL, and their receptors in the homeostasis of B-lymphocytes
BAFF and APRIL are native, constitutively produced immune modulators required for the development of B
lymphocytes within the bone marrow and for the maintenance of homeostasis of peripheral B lymphocytes at
rest as well as during immune responses. Both BAFF and APRIL have high affinity towards TACI; BAFF is also
capable of binding BAFF-R, and APRIL has high affinity towards BCMA [33]. Intracellular signaling triggered
by interactions between BAFF/APRIL proteins and their  receptors  proceeds  mainly via activation of TRAF
proteins and NF-κB (NF-κB) which result in increased proliferation of leukemic cells. Intracellular activation pathwaysB by canonical or non-canonical pathway [30,34]. NF-κB (NF-κB) which result in increased proliferation of leukemic cells. Intracellular activation pathwaysB is a transcription factor known to
play a key role in the expression of immunoglobulin genes as well as numerous genes responsible for survival,
activation, differentiation, and proliferation of lymphocytes [35]. In physiological conditions, the development
and functions of B cells are strictly regulated by numerous types of cells and factors secreted therefrom. As
shown in studies conducted to date, molecules of the TNF family are involved in said regulation both during the
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antigen-independent development of B lymphocytes within the bone marrow and during their proliferation and
activation following antigen exposure. Interactions of BAFF/APRIL proteins with their specific receptors within
the bone marrow enhances expression of paired box 5 (Pax5) transcription factor which, along with early B cell
factor (EBF) is a key transcription factor responsible for lymphoid progenitor differentiation into B lymphocyte
and involved in activation of plasma cells present within the bone marrow [36]. In addition, BAFF and APRIL
facilitate survival of B cells in peripheral lymphatic organs. The expression of these proteins is constitutive and
increases as the cells are stimulated with interferon, activation of TLR receptors or ligated by CD40 in the course
of ongoing inflammation. This is an additional observation supporting the suggested importance of the proteins
of interest in the immune response process. Particularly in the case of BAFF, it was demonstrated that once
bound to the BAFF-R, the protein enhances the expression of a number of antiapoptotic proteins of the Bcl-2
family, including B-cell lymphoma extra large (Bcl-XL), Bcl-2-like protein 11 (Bim) and myeloid cell leukemia
1 (Mcl-1) proteins within B lymphocytes [23, 26]. Pro-proliferative and pro-survival effects of BAFF are also
the result of protooncogene serine/threonine-protein kinase (Pim-1) and extracellular signal-regulated kinases
(ERK) activation, the enzymes are involved in the transmission of stimulatory signals to the cell nucleus, as well
as  activation of  molecules  involved  in  cell  cycle  regulation  such  as  cyclin  D,  p27Kip1,  or  c-myc proteins
[23,26,37]. The soluble form of BAFF is considered to the crucial for proper development of B lymphocytes in
the antigen-dependent  phase,  both within the lymph nodules  and the marginal  zone  [38].  By means  of  the
aforementioned  signaling  pathways,  BAFF  stimulates  not  only  the  proliferation  of  B  cells,  but  also  class
switching and production of antibodies, thus overseeing the correct course of humoral immune response [39].
Biological activity of APRIL is somewhat less understood compared to that of BAFF; however, APRIL was
shown to promote B cell survival at late development stages, stimulate proliferation of T and B cells, as well as
enhance class switching and production of antibodies [40]. In addition, together with IL-6 and SCF (stem cell
factor), APRIL is responsible for creating conditions promoting the survival of long-lived plasma cells within the
bone marrow [26]. By means of PI3K/AKT and MAP kinase pathway activation, BAFF and APRIL are also
involved in regulation of chemotaxis [41].
3.4. The role of BAFF, APRIL, and their receptors in the pathogenesis of CLL
The important role of BAFF and APRIL in the maintenance of survival and stimulation of proliferation of
B-lymphocytes suggests that overexpression of these proteins may deeply disrupt the control of these functions
and lead to carcinogenesis or autoimmune disorders [26]. The importance of these molecules for the regulation
of B cell biology was shown in a murine model study where a BAFF-R gene mutation leading to complete lack
of BAFF-R protein was demonstrated to be responsible for complete lack of B2 (CD5−) cells, which are the
main  systemic  subpopulation  of  B-lymphocytes  [38].  On  the  other  hand,  mice  with  artificially  activated
overexpression of APRIL gene were characterized by increased proliferation of B1 (CD5+) cells within the
peritoneum resulting in progressive hyperplasia of Peyer’s patches and mesenteric lymph nodes or even in B-cell
infiltrations of  parenchymal  abdominal  organs  [42].  To  date,  numerous  studies  were  initiated  to  assess  the
potential involvement of BAFF, APRIL and their receptors in the pathogenesis of chronic lymphocytic leukemia
in humans. One of the main findings consisted of a significantly increased levels of BAFF and APRIL within the
blood sera of patients diagnosed with CLL as compared to the control group consisting of healthy volunteers [33,
34]. The expression of BAFF and APRIL was also higher within the cell membranes as well as inside the B-
lymphocytes in CLL patients compared to healthy controls [33]. Other reports highlighted elevated levels of the
proteins of interest  on the surface  of monocyte-derived cells present  in the microenvironment  of  peripheral
lymph nodes (nurse-like cells) [34]. What’s more, studies of CLL showed that leukemic cells are characterized
not only by elevated levels of BAFF, APRIL and their receptors, but also by survival-stimulating signals being
received via these molecules as demonstrated in in vitro models [6,43]. BAFF and APRIL produced within the
microenvironment of lymphatic organs enhance the proliferation ability of leukemic cells by means of autocrine
as well as paracrine mechanisms, and are thus considered to be, along with excess activation of BCRs, the key
factor responsible for active proliferation and accumulation of leukemic cells within the lymphoid organs [44].
At the same time, literature data suggest that analogous increase is observed in patients diagnosed with CLL with
regard to the levels BAFF-R, TACI, and BCMA receptors on the surface of B cells present within the blood and
lymphatic tissue [6]. Interesting results were obtained in a study of intracellular expression of BAFF and APRIL
in  leukemic  B  cells  and  of  the  relationship  between  the  levels  of  these  proteins  and  certain  clinical  and
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prognostic parameters [33]. The levels of BAFF and APRIL proteins as assessed by cytometry was significantly
higher  in  CLL  B-cells  as  compared  to  B  cells  of  a  healthy  control  and  correlated  with  the  presence  of
unfavorable prognostic factors ZAP-70 and CD38 (no correlation was observed for IgVH mutation status). The
observed overexpression of BAFF and APRIL had negative impact on the overall survival (OS) in these patients.
In addition, the same study showed that also the elevated soluble APRIL serum levels in patients with CLL
determined by means of enzyme-linked immunosorbent assay (ELISA) is correlated with higher Rai stage and
shorter  overall  survival  [33].  The  results  are  all  the  more  interesting  that  they  suggest  the  potential  of
intracellular BAFF and APRIL (determined by means of cytometry) as well as soluble APRIL (determined in the
serum by means of ELISA) being useful as prognostic markers. The ease of the assays and the prognostic values
of these proteins suggested in studies conducted to date warrants their use in CLL prognosis being considered in
the future.  On the other  hand,  considering the complex and strong impact  of  BAFF/APRIL on the cellular
processes  (apoptosis,  cell  cycle control,  activation of intracellular  signaling pathways,  gene expression),  the
proteins may also be considered potential molecular targets for future therapy of chronic lymphocytic leukemia
[45].
4. Summary
CLL is the most common type of leukemia in the overall adult population in Western countries and the
morbidity rates of CLL are continually increasing. Despite numerous studies being undertaken to examine the
molecular background of the disease, the pathogenesis of CLL remains incompletely understood and the disease
remains incurable.  Accumulation of  leukemic cells  is  caused  by disturbed apoptosis;  however,  uncontrolled
activation and proliferation of cells secondary to BCR stimulation is equally important, and the original cause of
this phenomenon is still a subject of studies. Proteins of the TNF cytokine family are a large group of molecules
exerting complex impact on immune cell functions. By interaction with their specific receptors, two members of
this family, BAFF and APRIL, impact on the survival, proliferation, and numerous biological functions of B
cells.  It  was  demonstrated  that  interactions  between  these  proteins  and  their  receptors  trigger  a  number  of
molecular  effects  hitherto  observed  in  leukemic  cells,  such  as  inhibition  of  apoptosis,  activation  of  kinase
pathways involved in immune cell activation, and increased numbers of transcription factors involved in the
expression of genes responsible for survival and proliferation, suggesting their role in deregulation of B cells
which accompanies malignant transformation and chronic lymphocytic leukemia. CLL studies conducted to date
revealed  significantly  higher  levels  of  BAFF,  APRIL,  TACI,  BCMA,  and  BAFF-R  on  leukemic  B  cells
compared to B cells of healthy controls. At the same time, elevated levels of these proteins were shown to be
associated with higher clinical  stage and unfavorable prognosis.  Potential use of BAFF and APRIL or their
receptors and CLL prognostic markers in routine clinical practice requires numerous further studies; however,
considering the knowledge that has already been collected, the relatively simple methodology and low cost of
respective assays, the perspective is very interesting.
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